ArticleBlood2018
Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS.Haematologica · 2022Guideline
- AML with t(16;21)(p11.2;q22)/FUS::ERG rearrangement presenting with hemophagocytes and multinucleated cells: a case report and literature review.Annals of hematology · 2026Review
- Characterization of Acute Myeloid Leukemia With t(16;21) Translocation: Cytogenetic, Molecular, and Immunophenotypic Findings.World journal of oncology · 2026Article
- Review
- A Novel Approach to Prognostic Factors and Risk Stratification in Pediatric AML: Case Report and Literature Review.International journal of molecular sciences · 2025Review
- Novel classification system and high-risk categories of pediatric acute myeloid leukemia.Haematologica · 2025Review
- Integrating transcriptomics and hybrid machine learning enables high-accuracy diagnostic modeling for nasopharyngeal carcinoma.Discover oncology · 2025Article
- Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG.Leukemia · 2025Article
- PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia.Cancers · 2025Article
- [Mitoxantrone hydrochloride liposome combined with cytarabine for treating pediatric acute myeloid leukemia with RUNX1∷MTG16 fusion gene: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- A multiomic characterization of the leukemia cell line REH using short- and long-read sequencing.Life science alliance · 2024Article
- Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.Annals of hematology · 2024Review
- Rare Hematologic Malignancies and Pre-Leukemic Entities in Children and Adolescents Young Adults.Cancers · 2024Review
- Comprehensive analysis of clinical prognostic features and tumor microenvironment landscape of CD11bCellular oncology (Dordrecht, Netherlands) · 2023Article
- FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells.Scientific reports · 2023Article
- Acute pancreatitis as the initial manifestation of acute myeloid leukemia with chromosome 16 rearrangements.International journal of hematology · 2023Article
- Review
- Review
- Article
- Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration.Blood advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 20 institutions in 15 countries.
Sanne NoortPediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
Martin ZimmermannDepartment of Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany.
Dirk ReinhardtAcute Myeloid Leukemia-Berlin-Frankfurt-Münster Study Group, Pediatric Hematology and Oncology, Essen, Germany.
Wendy CuccuiniDepartment of Cytogenetics, Saint Louis Hospital, Paris, France.
Martina PigazziWomen and Children's Health, Hematology-Oncology Laboratory, University of Padova, Padova, Italy.
Jenny SmithFred Hutchinson Cancer Research Center, Seattle, WA.
Rhonda E RiesFred Hutchinson Cancer Research Center, Seattle, WA.
Todd A AlonzoChildren's Oncology Group, Monrovia, CA.
Betsy HirschChildren's Oncology Group, Monrovia, CA.
Daisuke TomizawaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.ORCID 0000-0003-1520-7007
Franco LocatelliDepartment of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Tanja A GruberDepartment of Oncology and.
Susana RaimondiDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Edwin SonneveldDutch Childhood Oncology Group, The Hague, The Netherlands.
Daniel K CheukDepartment of Pediatrics and Adolescent Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
Michael DworzakDepartment of Pediatrics, Children's Cancer Research Institute and St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
Jan StaryCzech Pediatric Hematology/Oncology, University Hospital Motol and Charles University, Prague, Czech Republic.
Jonas AbrahamssonNordic Society for Pediatric Hematology and Oncology, Department of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Nira Arad-CohenPediatric Hemato-Oncology Department, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
Malgorzata CzogalaDepartment of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.
Barbara De MoerlooseDepartment of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
Henrik HaslePediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0003-3976-9231
Soheil MeshinchiFred Hutchinson Cancer Research Center, Seattle, WA.
Marry van den Heuvel-EibrinkPediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
C Michel ZwaanPediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
Children's Oncology Group · USFred Hutch Cancer Center · USPrincess Máxima Center · NLAarhus University Hospital · DKCharles University · CZErasmus MC - Sophia Children’s Hospital · NLGhent University Hospital · BEHôpital Saint-Louis · FRJagiellonian University · PLMedizinische Hochschule Hannover · DENational Center For Child Health and Development · JPNordic Society for Pediatric Hematology and Oncology · SEQueen Mary Hospital · CNRambam Health Care Campus · ILSeattle Children's Hospital · USSt Anna Children's Hospital · ATStichting Kinderoncologie Nederland · NLSt. Jude Children's Research Hospital · USUniversity of Padua · ITUniversity of Pavia · IT
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MBiology/prognostic implications of Flt3 mutations in AMLR01CA114563 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MESHINCHI, SOHEIL · 2005 to 2016
$4.4MNCI NIH HHS R01 CA114563NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
Abstract
To study the prognostic relevance of rare genetic aberrations in acute myeloid leukemia (AML), such as t(16;21), international collaboration is required. Two different types of t(16;21) translocations can be distinguished: t(16;21)(p11;q22), resulting in the
Indexed as
Translocation, GeneticAdolescentChildChild, PreschoolChromosomes, Human, Pair 16Chromosomes, Human, Pair 21Core Binding Factor Alpha 2 SubunitFemaleGene Expression Regulation, LeukemicHumansInfantLeukemia, Myeloid, AcuteMalePrognosisRepressor ProteinsRetrospective StudiesCBFA2T3 protein, humanCore Binding Factor Alpha 2 SubunitERG protein, humanFUS protein, humanRepressor ProteinsRNA-Binding Protein FUSRUNX1 protein, humanTranscriptional Regulator ERGTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.